Related Experiment Videos
Immunomodulatory effects of rexinoids
1Medical Oncology, Yale Cancer Center, New Haven, CT 06520, USA. Francine.foss@yale.edu
Seminars in Oncology
|March 7, 2006
Summary
Rexinoids show promise for treating blood cancers by regulating cell growth and differentiation. Combining rexinoids with targeted therapies may improve outcomes for lymphoid malignancies.
Area of Science:
- Oncology
- Pharmacology
Background:
- Rexinoids modulate genes involved in cancer cell growth and differentiation.
- Hematologic malignancies, including cutaneous T-cell lymphomas, are targets for rexinoid therapy.
Purpose of the Study:
- To explore the therapeutic potential of rexinoids in lymphoid malignancies.
- To discuss combination strategies involving rexinoids and other treatments.
Main Methods:
- Review of rexinoid activity in hematologic malignancies.
- Discussion of combination therapies with interleukin-2 receptor-targeted agents (e.g., denileukin diftitox).
- Exploration of combining rexinoids with extracorporeal photophoresis.
Main Results:
- Rexinoids demonstrate clinical activity in hematologic malignancies.
- Combination therapies offer rational approaches for lymphoid malignancies.
Conclusions:
- Combining rexinoids with targeted therapies or extracorporeal photophoresis may enhance immunomodulatory effects.
- These combination strategies hold potential for improved clinical outcomes in lymphoid malignancies.